Website profile

Biospectrum Asia

Korea's ENCell partners with Andelyn Biosciences to expand global reach of gene therapy manufacturing BioSpectrum Asia BioSpectrum is an integrated B2B media platform for the healthcare and bioscience industry in the Asia Pacific region.

  • 166articles · 30d
  • 15+ hour agolatest article
  • Aug 18, 2026earliest in window
  • 92%with images
  • 260avg words
articles per day
Categories
  • Medical 109
  • Health & Wellness 98
  • Health 63
  • Business & Industrial 57
  • Science & Technology 51
  • Economy, Business & Finance 50
  • Science & Nature 31
  • Finance & Business 22

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

BioSpectrum Asia
biospectrumasia.com > analysis > 29 > 28327 > 10-decisions-every-life-sciences-ceo-must-make-before-q4-planning-closes.html

10 Decisions Every Life Sciences CEO Must Make Before Q4 Planning Closes

1+ week, 1+ hour ago   (153+ words) September 7, 2026 | Monday | Analysis | By Ankit Kankar | [email protected] Every planning season produces the same quiet moment. The forecasts are built, the templates have gone around twice, and what remains on the table is a short list of questions that no…...

BioSpectrum Asia
biospectrumasia.com > news > 55 > 28254 > gc-biopharmas-hunter-syndrome-treatment-hunterase-receives-drug-approval-in-india-and-taiwan.html

GC Biopharma's Hunter Syndrome treatment 'Hunterase' receives drug approval in India and Taiwan

2+ week, 6+ day ago   (230+ words) August 24, 2026 | Monday | News GC Biopharma, a leading global pharmaceutical company based in South Korea, has announced that its Hunter syndrome treatment, 'Hunterase IV', has received marketing authorisation from India's Central Drugs Standard Control Organisation (CDSCO) and Taiwan's Food and Drug…...

BioSpectrum Asia
biospectrumasia.com > influencers > 102 > 28246 > china-biotechs-global-breakout-innovation-deals-and-the-next-investment-cycle.html

China Biotech’s Global Breakout: Innovation, Deals and the Next Investment Cycle

2+ week, 6+ day ago   (344+ words) August 24, 2026 | Monday | Influencers | By Ankit Kankar | [email protected] China’s biotech and pharmaceutical sector is entering a new phase of global relevance. A surge in out-licensing deals, increasingly competitive innovation, improving financial performance and attractive valuations are drawing renewed investor attention to…...